63. 特発性血小板減少性紫斑病 [臨床試験数:311,薬物数:185(DrugBank:39),標的遺伝子数:43,標的パスウェイ数:132

Searched query = "Idiopathic thrombocytopenic purpura", "Primary immune thrombocytopenia"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
19 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1ChiCTR20000354082020-08-202020-08-10A randomized controlled study for rituximab in first-line treatment of newly diagnosed immune thrombocytopeniaStudy of rituximab in first-line treatment of newly diagnosed immune thrombocytopenia Idiopathic Thrombocytopenic PurpuraStandard dose group:Rituximab (Hanrikang) 375mg/m2, 4 times a week (day 8, 15, 22, 29).;Low-dose group:Rituximab (Hanrikang) 100mg/ time once a week, administered 4 times (day 8, 15, 22 and 29).;Dexamethasone control group:high-dose dexamethasone (HD-DXM), 40mg/d, iv for 4 days (day 1 to day 4), every 15 days, 2 to 4 cycles, until CR or the end of the study.;Henan Cancer HospitalNULLRecruiting1865BothStandard dose group:20;Low-dose group:20;Dexamethasone control group:20;China
2ChiCTR19000277352020-01-012019-11-24Clinical study for high-dose dexamethasone combined with versus without human recombinant thrombopoietin (rhTPO) in the treatment of newly diagnosed primary immune thrombocytopenia (ITP)Clinical study for high-dose dexamethasone combined with versus without human recombinant thrombopoietin (rhTPO) in the treatment of newly diagnosed primary immune thrombocytopenia (ITP) Adult newly diagnosed immune thrombocytopeniaStudy group:Dexamethasone 40mg/d×4d, recombinant human thrombopoietin (rhTPO) 300U/Kg subcutaneous injection, once/d×14d, if PLT>100×109/L or PLT increase =50×109/L during treatment period RhTPO drug was discontinued; rhTPO and dexamethasone were replaced with prednisone 0.5mg~1mg/kg once a day, 0.2mg/kg per week, and the drug was stopped wit;Control group:Dexamethasone 40mg/d×4d, if the PLT>100×10^9/L or PLT increase =50×10^9/L during the treatment period, dexamethasone was replaced with prednisone 0.5mg~ 1mg/kg orally every day, reduce 0.2mg/kg per week, and quickly reduce the dose within 6~8 weeks.;Department of Hematology, Anhui Provincial HospitalNULLPending1880BothStudy group:30;Control group:30;China
3JPRN-jRCTs04119006901/10/201925/09/2019Clinical study to evaluate the efficacy of dexamethasone Palmitate for idiopathic (immune) thrombocytopenic purpura: ITP.Clinical Investigation to evaluate the efficacy of dexamethasone palmitate for idiopathic (immune) thrombocytopenic purpura: ITP. - Clinical investigation of Dexamethasone Palmitate for ITP Chronic Idiopathic Thrombocytopenic Purpura
refractory, immune, thrombocytopenia,;D016553
Administration of dexamethasone palmitate (5mg/day for 4 days)Nakayama TakayukiNULLRecruiting>= 20age old<= 75age oldBoth7Japan
4NCT03998982June 25, 201925/6/2019Glycyrrhetinic Acid Combined With Dexamethasone in Management of Newly Diagnosed ITPA Single-center Prospective Randomized Study of Glycyrrhetinic Acid Combined With Dexamethasone in the Treatment of Newly Diagnosed Primary Immune Thrombocytopenia (ITP)Immune ThrombocytopeniaDrug: Glycyrrhetinic Acid;Drug: DexamethasoneShandong UniversityNULLRecruiting18 Years80 YearsAll30Phase 4China
5NCT03252457September 1, 201814/8/2017Decitabine Combining Dexamethasone Versus Dexamethasone in Management of ITPA Multicenter Prospective Randomized Study of Dexamethasone Combined With Decitabine Versus Dexamethasone in the Treatment of Newly Diagnosed Primary Immune Thrombocytopenia (ITP)Purpura, Thrombocytopenic, Idiopathic;Immune ThrombocytopeniaDrug: Decitabine;Drug: DexamethasoneShandong UniversitySecond Affiliated Hospital of Medical College Shandong University;Shandong Provincial Hospital;Qingdao Central Hospital;Chinese Academy of Medical SciencesNot yet recruiting18 Years75 YearsAll200Phase 3China
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT03830749July 1, 20181/2/2019Safety and Efficacy of Eltrombopag Plus Pulsed Dexamethasone for Subjects With Idiopathic Thrombocytopenic PurpuraA Pilot Study to Evaluate the Safety and Efficacy of Eltrombopag Plus Pulsed Dexamethasone as First Line Therapy for Subjects With Idiopathic Thrombocytopenic Purpura (ITP)Immune ThrombocytopeniaDrug: EltrombopagHumanity & Health Medical Group LimitedNULLRecruiting18 YearsN/AAll60Phase 2Hong Kong
7NCT02914054October 1, 201619/9/2016Therapy of Adults Affected by Idiopathic Thrombocytopenic Purpura With DexamethasoneTherapy of Adults Affected by Idiopathic Thrombocytopenic Purpura With 3 Cycles Pulses of High-dose Dexamethasone (HD-DXM)ITP;Croticosteroid TherapyDrug: High dose Dexamethasone pulses;Drug: PrednisoneIsfahan University of Medical SciencesAdibviraCompleted18 YearsN/AAll36Phase 2/Phase 3Iran, Islamic Republic of
8NCT02642380November 201524/12/2015Different Cycles of High-dose Dexamethasone for Initial Management of Primary Immune Thrombocytopenia (ITP)Different Cycles of High-dose Dexamethasone for Initial Management of Primary Immune Thrombocytopenia (ITP): a Prospective, Randomized Controlled TrialImmune ThrombocytopeniaDrug: Dexamethasone (4 cycles);Drug: Dexamethasone (1 cycle)Shandong UniversityNULLWithdrawn18 Years75 YearsBoth0Phase 4China
9NCT02556814September 201521/9/2015Caffeic Acid Combining High-dose Dexamethasone in Management of ITPA Prospective, Multicenter, Placebo Controlled Study on Caffeic Acid Tablet Combining High-dose Dexamethasone in Management of Adult Primary Immune Thrombocytopenia (ITP)Immune ThrombocytopeniaDrug: Caffeic acid tablets;Drug: Dexamethasone;Drug: placeboShandong UniversityNULLCompleted18 Years75 YearsAll214Phase 4China
10ChiCTR19000212112015-04-012019-02-01A pilot study for evaluation of the safety and efficacy of eltrombopag plus pulsed dexamethasone as first line therapy for subjects with idiopathic thrombocytopenic purpura (ITP)A pilot study for evaluation of the safety and efficacy of eltrombopag plus pulsed dexamethasone as first line therapy for subjects with idiopathic thrombocytopenic purpura (ITP) immune thrombocytopenia (ITP)1:eltrombopag 25-75mg daily for 3 months plus pulsed dexamethasone, 40mg daily for 4 days repeated every 4 weeks for 1-3 courses;University Hospital, MacauNULLRecruiting18100Both1:60;China
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11NCT01882127February 201319/4/2013All-Trans Retinoic Acid (ATRA) Combining Dexamethasone Versus High-dose Dexamethasone for Initial Treatment of Primary Immune Thrombocytopenia (ITP)Clinical Study on All-Trans Retinoic Acid (ATRA) Combining High-dose Dexamethasone Versus High-dose Dexamethasone Alone for Initial Treatment of Primary Immune Thrombocytopenia (ITP)Purpura;Idiopathic Thrombocytopenic PurpuraDrug: All-Trans Retinoid Acid(ATRA);Drug: DexamethasoneShandong UniversityNULLWithdrawn18 Years75 YearsBoth0Phase 3China
12NCT01734057July 201221/11/2012Recombinant Human Thrombopoietin (rhTPO) Combining Rituximab Versus High-dose Dexamethasone for Initial Treatment of Primary Immune Thrombocytopenia (ITP)A Multicentre Investigation of Recombinant Human Thrombopoietin (rhTPO) Combining Rituximab Versus High-dose Dexamethasone for Initial Treatment of Primary Immune Thrombocytopenia (ITP)Purpura;Idiopathic Thrombocytopenic PurpuraDrug: recombinant human thrombopoietin (rhTPO); rituximab;Drug: DexamethasoneShandong UniversityThe Affiliated Hospital of the Chinese Academy of Military Medical Sciences;Anhui Medical University;The First Affiliated Hospital of Dalian Medical University;Shandong Provincial Hospital;Shenzhen Second People's Hospital;China Medical University, China;Zhejiang Provincial Hospital of TCMWithdrawn18 Years75 YearsBoth0Phase 3China
13NCT01734044July 201221/11/2012rhTPO Combining Dexamethasone Versus High-dose Dexamethasone for Initial Treatment of ITPA Multicentre Investigation of Recombinant Human Thrombopoietin (rhTPO) Combining Dexamethasone Versus High-dose Dexamethasone for Initial Treatment of Primary Immune Thrombocytopenia (ITP)Purpura;Idiopathic Thrombocytopenic PurpuraDrug: recombinant human thrombopoietin (rhTPO); dexamethasone;Drug: DexamethasoneShandong UniversityThe Affiliated Hospital of the Chinese Academy of Military Medical Sciences;Anhui Medical University;The First Affiliated Hospital of Dalian Medical University;Shandong Provincial Hospital;Shenzhen Second People's Hospital;China Medical University, China;Zhejiang Provincial Hospital of TCMCompleted18 Years75 YearsBoth158Phase 3China
14NCT01356511September 201017/5/2011High-dose Dexamethasone Versus Conventional Dose Prednisone for Initial Treatment of Primary Immune Thrombocytopenia (ITP)High-dose Dexamethasone and Conventional Dose Prednisone, for the First-line Treatment of Adults With ITP: a Multicenter, Randomized Controlled, Clinical TrialPurpura, Thrombocytopenic, IdiopathicDrug: Prednisone;Drug: DexamethasoneShandong UniversityChinese Academy of Medical Sciences;Peking Union Medical College Hospital;Ruijin Hospital;Wuhan Union Hospital, China;Tongji Hospital;Shandong University of Traditional Chinese Medicine;Anhui Provincial Hospital;Zhejiang Provincial Hospital of TCM;Second Hospital of Shanxi Medical University;Xinjiang Uygur Autonomous Region People's Hospital;Shenzhen Second People's HospitalCompleted18 Years80 YearsBoth261Phase 4China
15EUCTR2008-000417-30-IT19/06/200811/04/2008Randomized study for the treatment of primary Immune Thrombocytopenic Purpura (ITP) in newly diagnosed untreated adult patients. Comparison of standard dose prednisone versus high-dose Dexamethasone. GIMEMA Protocol ITP0207 - GIMEMA ITP0207Randomized study for the treatment of primary Immune Thrombocytopenic Purpura (ITP) in newly diagnosed untreated adult patients. Comparison of standard dose prednisone versus high-dose Dexamethasone. GIMEMA Protocol ITP0207 - GIMEMA ITP0207 ITP Primary Immune Thrombocytopenic Purpura in newly diagnosed untreated adult patients
MedDRA version: 9.1Level: LLTClassification code 10021245Term: Idiopathic thrombocytopenic purpura
Product Name: Dexamethasone
INN or Proposed INN: Dexamethasone
Product Name: Prednisone
INN or Proposed INN: Prednisone
G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTONULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Italy
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
16NCT00451594September 200522/3/2007High Dose Dexamethasone Vs. Conventional Dose Prednisolone in Adult ITPA Randomized Controlled Multicentre Trial of High Dose Dexamethasone Versus Conventional Dose Prednisolone for Adults With Untreated Idiopathic Thrombocytopenic PurpuraIdiopathic Thrombocytopenic PurpuraDrug: Dexamethasone;Drug: PrednisoloneCooperative Study Group A for HematologyNULLCompleted16 YearsN/ABoth157Phase 3Korea, Republic of
17NCT00770562July 20059/10/2008A Study Evaluating the Addition of MabThera (Rituximab) to Standard Treatment in Patients With Idiopathic Thrombocytopenic Purpura (ITP)A Randomized, Open-label Study of First-line Treatment With Dexamethasone or Dexamethasone Plus MabThera on Sustained Treatment Response in Adult Patients With Idiopathic Thrombocytopenic PurpuraIdiopathic Thrombocytopenic PurpuraDrug: rituximab;Drug: DexamethasoneHoffmann-La RocheNULLCompleted18 YearsN/AAll103Phase 3Italy
18EUCTR2005-000859-15-IT14/04/200520/06/2005Randomized prospective study comparing dexamethasone and dexamethasone plus rituximab in the treatment of idiopathic thrombocytopenic purpura (ITP) in adults.Randomized prospective study comparing dexamethasone and dexamethasone plus rituximab in the treatment of idiopathic thrombocytopenic purpura (ITP) in adults. Front-line treatment of adult ITP
MedDRA version: 6.1Level: PTClassification code 10021245
Trade Name: Mabthera
INN or Proposed INN: Rituximab
Trade Name: Mabthera
INN or Proposed INN: Rituximab
ROCHENULLNot RecruitingFemale: yes
Male: yes
Italy
19NCT00909077August 200426/5/2009The Efficacy of Dexamethasone Versus Dexamethasone Combined With Rituximab in Patients With Newly Diagnosed Idiopathic Thrombocytopenic Purpura (ITP)A Randomised Phase III Study of the Efficacy of High Dose Dexamethasone Versus High Dose Dexamethasone in Combination With Rituximab (MabThera®)in Patients With Newly Diagnosed Idiopathic Thrombocytopenic Purpura (ITP)Idiopathic Thrombocytopenic PurpuraDrug: Dexamethasone;Drug: Dexamethasone and RituximabCopenhagen University Hospital at HerlevNULLCompleted18 YearsN/AAll155Phase 3Denmark